Breast Cancer

BREAST CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
PARP Inhibition Plus Macrophage-Targeting Therapy Emerges as Promising Strategy in BRCA1-Associated TNBC

This study investigates the mechanisms behind anti-CSF1R therapy and PARP inhibition’s reduction of pro-tumor macrophages in triple-negative breast cancer.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
A Tool Meant to Catch Distress in Patients With Breast Cancer May Overlook the True Needs of Black Women

The pitfall of self-reported stress levels is that the baseline stress for some people is so high, a cancer diagnosis doesn’t even register.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.

VIDEO SERIES

The Phase 3 PlanB Trial

Continue to Work?

Drug Resistance to CDK4/6 Inhibitors

Comparing Ribociclib and Palbociclib

Ribociclib, Abemaciclib, and Palbociclib

The Potential of CDK4/6 Inhibitors

How Cyclin D Plays A Role

2016 SABCS: Clinical Insights Telli

2016 SABCS: Clinical Insights Oregan

HER2-positive Metastatic and TNBC

Frontline Treatments

Treatment-related Neuropathy

ER-positive, HER2-negative

Emerging Medicines

Triple-negative Breast Cancer

Insights from the Lab and Clinic

Trastuzumab Resistance

Biologic Role of HER2

Strategies in Management

BREAST CANCER NEWS

During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.

Most Patients With Breast, Ovarian Cancer Patients Do Not Undergo Genetic Testing

March 1, 2021

A clinician observes the results of a genetic test on their tablet.

Protein-Truncating and Rare Missense Variants Associated With Risk for Breast Cancer

February 23, 2021

Trastuzumab emtansine reduces the risk of recurrence by 50% in some HER2-positive breast cancers following neoadjuvant chemotherapy.

Estradiol Challenge Test ‘Highly Predictive’ of Response to Endocrine Therapy in Patients With ER-Positive Breast Cancer

February 17, 2021

Gonadotropin-Releasing Hormone Analogue Worsens Treatment-Related Adverse Effects in Male Breast Cancer

February 12, 2021

A study affirmed the benefits of a multimodal approach in the assessment of minimal residual disease in multiple myeloma.

SOPHIA Study Data Published in JAMA Oncology

February 2, 2021

Next post in Breast Cancer

A clinician observes the results of a genetic test on their tablet.

Protein-Truncating and Rare Missense Variants Associated With Risk for Breast Cancer